01 October 2005
Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonistsfor postoperative nausea and vomiting.
Piotr K JanickiMed Sci Monit 2005; 11(10): RA322-328 :: ID: 430339
Abstract
Postoperative nausea and vomiting (PONV) affects approximately one thirdof patients and may lead to aspiration, dehiscence, esophageal rupture, and increased treatment costsif inadequately controlled. An important therapeutic option for prevention of PONV is 5-hydroxytryptaminetype 3 (5-HT3) receptor antagonists. Nonetheless, therapeutic failure sometimes occurs. Metabolism bythe cytochrome P450 (CYP) system differs among the 5-HT3 receptor antagonists, and provides a rationalexplanation for decreased therapeutic efficacy in some patients. Four of the 5-HT3 receptor antagonistagents (dolasetron, ondansetron, palonosetron, and tropisetron) are metabolized in various degrees viaCYP2D6, an isoform subject to marked genetic polymorphism. In patients with duplicate CYP2D6 alleles,degradation into inactive metabolites occurs rapidly with these four 5-HT3 receptor antagonists, resultingin decreased efficacy for preventing PONV. Granisetron is the only agent in this class that is not metabolizedvia CYP2D6. Instead, granisetron is metabolized via the CYP3A4 isoform, which is not subject to significantgenetic polymorphism. CYP2D6 genotype screening prior to PONV treatment may allow for modification ofantiemetic dosing. An alternative is to use a 5-HT3 agent that is metabolized independently of the CYP2D6isoform, such as granisetron, that would obviate the need for genotyping and may lead to improved prophylaxisof PONV.
Keywords: Genotype, Cytochrome P-450 Enzyme System - metabolism, Cytochrome P-450 CYP2D6 - metabolism, Postoperative Nausea and Vomiting - prevention & control, Serotonin 5-HT3 Receptor Antagonists, Serotonin Antagonists - therapeutic use
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952